Navigation Links
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Date:7/8/2009

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investigator of the trial will discuss results of the Company's Phase 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters.

Conference Call and Webcast Information

To access the live call, please dial 866-543-6408 (domestic) or 617-213-8899 (international) 10 minutes prior to the start time and use the passcode 40038100. A replay of the call will be available at approximately 11:30 a.m. EDT on July 9, 2009 until July 16, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 48864759. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... , Feb. 9 Palatin ... announced the completion of first cohort dosing in ... experimental treatment for sexual dysfunction.  The primary endpoint ... blood pressure effects of subcutaneous bremelanotide in men ... will also evaluate consistency of plasma exposure of ...
(Date:2/9/2010)... February 9 Debiopharm Group,(Debiopharm), ... with,a focus on the development of prescription ... the signature of an exclusive licence agreement ... of Debio 025,(alisporivir), a selective, first-in-class cyclophilin ... (HCV) effect. The product is currently in ...
(Date:2/8/2010)... PreXion, Inc., ( www.prexion.com ) ... systems for dentistry, today announced that it has appointed ... ,, PreXion President/COO Robert Meier commented, "We ... team and I look forward to working with him ... experience and success in the dental and high tech ...
Breaking Medicine Technology:Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3PreXion, Inc. Announces Appointment of Director of Marketing 2UNC study pinpoints gene controlling number of brain cells 10250 1UNC study pinpoints gene controlling number of brain cells 10250 2Care Workers Key Members of Interdisciplinary Health Care Team 58825 1Care Workers Key Members of Interdisciplinary Health Care Team 58825 2Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 1Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 2Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 3Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 4
... 2007 (BUSINESS WIRE) -- MGI PHARMA, INC.,(NASDAQ:MOGN), ... care, today announced the presentation of results ... Aquavan(R) (fospropofol,disodium) Injection in patients undergoing colonoscopy. ... as safety data, were,presented at Digestive Disease ...
... * Ozarelix Effective in Improving Symptoms and Urine ... IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Spectrum,Pharmaceuticals, ... for ozarelix, the Company's drug candidate for the ... Urology,Association Annual Meeting held at the Anaheim Convention ...
Other Medicine Technology:Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 2Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 3Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 4Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 5Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5
(Date:2/9/2010)... Reptiles are bred in captivity primarily for their skins, ... for their meat. A study shows that eating these ... the wisdom of eating this ,delicacy., , Parasites, bacteria ... heavy metals and residues of veterinary drugs- eating reptile ... the conclusion of a study published in the ...
(Date:2/9/2010)... Idaho Lose $1.6 Billion from Feds & Thousands ... 9 As the Idaho House approved legislation ... care law, the long-term effects of the move could be ... Health Freedom Act (House Bill 391) a disastrous and problem-riddled ... Idaho lose nearly $1.6 billion in ...
(Date:2/9/2010)... Michigan State University has launched the nation,s first ... product counterfeiting- which the FBI has called "the ... of products- from pharmaceuticals to food additives to ... dollars in global trade and has a major ... environment and national security. Terrorist and other organized ...
(Date:2/9/2010)... born prematurely in the US, according to data presented ... findings were reported at the 30th Annual Meeting of ... were published in the latest issue of the ... reported that CP is associated with inflammation of the ... more common in premature births from preterm labor and ...
(Date:2/9/2010)... Feb. 9 The following is a ... ,, "Reversing the childhood obesity epidemic will require the ... demonstrated today. ,, "As the First Lady ... with chips and soda -- and few healthy food ... bleak food landscape extends far beyond the school yard. ...
Breaking Medicine News(10 mins):Health News:Study carried out into biological risks of eating reptiles 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4Health News:MSU launches first anti-counterfeiting research program 2Health News:MSU launches first anti-counterfeiting research program 3Health News:Incidence of cerebral palsy on rise in US 2
... is improved by incorporation of folic acid in the diet, ... that folic acid supplementation during pregnancy can reduce the incidence ... ,The researchers analyzed the effect of consumption of ... spina bifida between the year 1998 and 2001. 92% of ...
... on high alert after it was confirmed that the dreaded bird ... after it was confirmed that a cat had died of bird ... to ward off the disease. // Federal Agriculture and Protection of ... of the bird flu will be kept inside homes, while it ...
... Ontario and followed over two years, researchers found that only 66 ... author of the study by the Institute of Clinical Evaluative Sciences ... around 19 times in two years. It was later found that ... are not keeping good health and are not going in for ...
... the ban on smoking in public places to be enforced, a ... habit for good on the National No Smoking Day. // ... nearly 6.3 million in the UK have died due to smoking. ... organizers, nearly 41 per cent of smokers - around five million ...
... London has decided to offer free fertility treatment to unmarried ... free pilot scheme has been initiated just in time,// before ... ,Although many fell that the move would destabilize traditional ... it could mean the ultimate in women liberation. There has ...
... follow-up of a TB case in Aberdeen. ,Six people ... heath officials are reassuring the public, not to worry. // ... contact with all those who attended Friday prayers at Aberdeen City ... the doctors say that the six patients who were diagnosed with ...
Other Medicine News:Health News:Vaccination Schedules Rates among Canadian Kids Dip Low 2
... Delivery System incorporates a translucent inner sleeve ... confidence that each needle load matches the ... other preloaded needle options, the IsoSleeve™ system ... configuration giving you confidence that the needle ...
... The Quinton Q-Track II Holter Monitoring ... company that produced the worlds first true ... true 12-lead presentation of any beat contained ... segment analysis. , ,The preprocessing work done ...
... been designed as a compact, cost-effective and ... private clinics or as a second system. ... most commonly required investigations such as Uroflowmetry, ... Add-on options are available for Urethral Pressure ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
Medicine Products: